28404899|t|BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH / gL induced comparable serum neutralizing antibody activity to UV - inactivated KSHV
28404899|a|Infection with Kaposi sarcoma-associated herpesvirus (KSHV) is estimated to account for over 44,000 new cases of Kaposi sarcoma annually, with 84% occurring in Africa, where the virus is endemic. To date, there is no prophylactic vaccine against KSHV. KSHV gpK8.1, gB, and gH / gL glycoproteins, implicated in the virus entry into host cells, are attractive vaccine targets for eliciting potent neutralizing antibodies (nAbs) against virus infection. We incorporated gpK8.1, gB, or gH / gL on the surface of virus-like particles (VLPs) and characterized these VLPs for their composition, size, and functionality. To determine which viral glycoprotein(s) elicit the most effective serum - nAbs, we immunized BALB/c mice with gpK8.1, gB, or gH / gL VLPs individually or in combination. Neutralizing antibody assay revealed that sera from mice immunized with the VLPs inhibited KSHV infection of HEK-293 cells in a dose-dependent manner. As a single immunogen, gpK8.1 VLPs stimulated comparable nAb activity to that of UV - inactivated KSHV (UV-KSHV). In contrast, UV-KSHV stimulated higher titers of nAb compared to gB (p = 0.0316) or gH / gL (p = 0.0486). Mice immunized with the combination of gB and gH / gL VLPs had a better nAb response than those immunized with either gB (p = 0.0268), or gH /gL (p = 0.0397) as single VLP immunogens. Immunization with any VLP combination stimulated comparable nAb activity to UV-KSHV serum. Our data provide the first evidence that KSHV gpK8.1, gB, and gH / gL glycoproteins can be incorporated onto the surface of VLPs and used as prophylactic vaccine candidates, with potential to prevent KSHV infection.
28404899	0	11	BALB/c mice	T204	UMLS:C0025919
28404899	12	21	immunized	T058	UMLS:C0020971
28404899	44	64	virus-like particles	T017	UMLS:C0333785
28404899	79	116	Kaposi sarcoma-associated herpesvirus	T005	UMLS:C0376526
28404899	118	122	KSHV	T005	UMLS:C0376526
28404899	133	153	glycoproteins gpK8.1	T103	UMLS:C0767120
28404899	155	157	gB	T103	UMLS:C0761135
28404899	163	165	gH	T103	UMLS:C1142879
28404899	168	170	gL	T103	UMLS:C2606403
28404899	190	195	serum	T031	UMLS:C0229671
28404899	196	217	neutralizing antibody	T103	UMLS:C0475463
28404899	218	226	activity	T038	UMLS:C1621287
28404899	247	251	KSHV	T005	UMLS:C0376526
28404899	267	304	Kaposi sarcoma-associated herpesvirus	T005	UMLS:C0376526
28404899	306	310	KSHV	T005	UMLS:C0376526
28404899	365	379	Kaposi sarcoma	T038	UMLS:C0036220
28404899	412	418	Africa	T082	UMLS:C0001737
28404899	430	435	virus	T005	UMLS:C0376526
28404899	469	489	prophylactic vaccine	T103	UMLS:C0042210
28404899	498	502	KSHV	T005	UMLS:C0376526
28404899	504	508	KSHV	T005	UMLS:C0376526
28404899	509	515	gpK8.1	T103	UMLS:C0767120
28404899	517	519	gB	T103	UMLS:C0761135
28404899	525	527	gH	T103	UMLS:C1142879
28404899	530	546	gL glycoproteins	T103	UMLS:C2606403
28404899	566	571	virus	T005	UMLS:C0376526
28404899	583	593	host cells	T017	UMLS:C1819995
28404899	610	617	vaccine	T103	UMLS:C0042210
28404899	647	670	neutralizing antibodies	T103	UMLS:C0475463
28404899	672	676	nAbs	T103	UMLS:C0475463
28404899	686	701	virus infection	T038	UMLS:C0042769
28404899	719	725	gpK8.1	T103	UMLS:C0767120
28404899	727	729	gB	T103	UMLS:C0761135
28404899	727	729	gB	T103	UMLS:C0761135
28404899	734	736	gH	T103	UMLS:C1142879
28404899	739	741	gL	T103	UMLS:C2606403
28404899	760	780	virus-like particles	T017	UMLS:C0333785
28404899	782	786	VLPs	T017	UMLS:C0333785
28404899	812	816	VLPs	T017	UMLS:C0333785
28404899	884	905	viral glycoprotein(s)	T017	UMLS:C1325834
28404899	932	937	serum	T031	UMLS:C0229671
28404899	940	944	nAbs	T103	UMLS:C0475463
28404899	949	958	immunized	T058	UMLS:C0020971
28404899	959	970	BALB/c mice	T204	UMLS:C0025919
28404899	976	982	gpK8.1	T103	UMLS:C0767120
28404899	984	986	gB	T103	UMLS:C0761135
28404899	991	993	gH	T103	UMLS:C1142879
28404899	996	998	gL	T103	UMLS:C2606403
28404899	999	1003	VLPs	T017	UMLS:C0333785
28404899	1036	1057	Neutralizing antibody	T103	UMLS:C0475463
28404899	1088	1092	mice	T204	UMLS:C0025919
28404899	1093	1102	immunized	T058	UMLS:C0020971
28404899	1112	1116	VLPs	T017	UMLS:C0333785
28404899	1127	1131	KSHV	T005	UMLS:C0376526
28404899	1132	1141	infection	T038	UMLS:C0042769
28404899	1145	1158	HEK-293 cells	T017	UMLS:C2936239
28404899	1199	1208	immunogen	T103	UMLS:C0003320
28404899	1210	1216	gpK8.1	T103	UMLS:C0767120
28404899	1217	1221	VLPs	T017	UMLS:C0333785
28404899	1244	1247	nAb	T103	UMLS:C0475463
28404899	1285	1289	KSHV	T005	UMLS:C0376526
28404899	1291	1298	UV-KSHV	T005	UMLS:C0376526
28404899	1314	1321	UV-KSHV	T005	UMLS:C0376526
28404899	1366	1368	gB	T103	UMLS:C0761135
28404899	1385	1387	gH	T103	UMLS:C1142879
28404899	1390	1392	gL	T103	UMLS:C2606403
28404899	1407	1411	Mice	T204	UMLS:C0025919
28404899	1412	1421	immunized	T058	UMLS:C0020971
28404899	1446	1448	gB	T103	UMLS:C0761135
28404899	1453	1455	gH	T103	UMLS:C1142879
28404899	1458	1460	gL	T103	UMLS:C2606403
28404899	1461	1465	VLPs	T017	UMLS:C0333785
28404899	1503	1512	immunized	T058	UMLS:C0020971
28404899	1525	1527	gB	T103	UMLS:C0761135
28404899	1545	1547	gH	T103	UMLS:C1142879
28404899	1575	1578	VLP	T017	UMLS:C1325725
28404899	1579	1589	immunogens	T103	UMLS:C0003320
28404899	1591	1603	Immunization	T058	UMLS:C0020971
28404899	1613	1616	VLP	T017	UMLS:C1325725
28404899	1651	1654	nAb	T103	UMLS:C0475463
28404899	1667	1674	UV-KSHV	T005	UMLS:C0376526
28404899	1675	1680	serum	T031	UMLS:C0229671
28404899	1723	1727	KSHV	T005	UMLS:C0376526
28404899	1728	1734	gpK8.1	T103	UMLS:C0767120
28404899	1736	1738	gB	T103	UMLS:C0761135
28404899	1744	1746	gH	T103	UMLS:C1142879
28404899	1749	1765	gL glycoproteins	T103	UMLS:C2606403
28404899	1806	1810	VLPs	T017	UMLS:C0333785
28404899	1823	1843	prophylactic vaccine	T103	UMLS:C0042210
28404899	1882	1886	KSHV	T005	UMLS:C0376526
28404899	1887	1896	infection	T038	UMLS:C0042769